Loading…
Aclarion, Inc. is projected to rise to $3.60 by 2027, a +15% move from its current price of $3.12. ACON is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.02 | $3.12 | $3.22 | -0.02% |
| May 30 | $2.98 | $3.12 | $3.27 | -0.04% |
| May 31 | $2.94 | $3.12 | $3.30 | -0.06% |
| Jun 1 | $2.92 | $3.12 | $3.33 | -0.07% |
| Jun 2 | $2.89 | $3.12 | $3.36 | -0.09% |
| Jun 3 | $2.87 | $3.12 | $3.38 | -0.11% |
| Jun 4 | $2.85 | $3.12 | $3.40 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.85 | $3.12 | $3.40 | -0.13% |
| Week 2 | $2.75 | $3.11 | $3.52 | -0.26% |
| Week 3 | $2.67 | $3.11 | $3.62 | -0.39% |
| Week 4 | $2.61 | $3.10 | $3.70 | -0.52% |
| Week 5 | $2.55 | $3.10 | $3.77 | -0.65% |
| Week 6 | $2.50 | $3.10 | $3.84 | -0.77% |
| Week 7 | $2.45 | $3.09 | $3.90 | -0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Aclarion, Inc. (ACON) is a healthcare technology company with a focus on magnetic resonance spectroscopy (MRS) based biomarkers for spine health. Its current price is $3.21 and its market capitalization is $7.9M, with a rank of 5227.
The asset trades within a framework of defined support and resistance levels and a 30-day price range, reflecting the near-term market posture.
A major floor 24.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.6% away) — a key level to hold.
The nearest ceiling, 19.6% above — a clean break opens room to run.
A major ceiling 26.5% above — clearing it would confirm fresh momentum.
Key ACON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.19 | Sell | $3.17 | Sell |
| MA 10 | $3.20 | Sell | $3.19 | Sell |
| MA 20 | $3.22 | Sell | $3.22 | Sell |
| MA 50 | $3.29 | Sell | $3.31 | Sell |
| MA 100 | $3.38 | Sell | $6.15 | Sell |
| MA 200 | $5.26 | Sell | $274.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.84 | Neutral |
| Stoch RSI (14) | 13.71 | Buy |
| CCI (20) | -111.02 | Sell |
| Williams %R (14) | -88.89 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -2.04 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 11.11 | Buy |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 42.11 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.17 | Sell |
| ADX (14) | 7.23 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is neutral, with RSI14 at 50. The near-term momentum sits around the middle of the range, aligning with a neutral stance. The stock’s SMA50 is $3.30, while the SMA200 sits at $5.30, indicating a potential longer-term drift if momentum strengthens.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.36 | $3.12 | $4.30 | 0% | Neutral | |
| $2.79 | $3.60 | $4.94 | +15% | Neutral | |
| $2.42 | $3.22 | $4.61 | +3% | Neutral | |
| $2.43 | $3.33 | $4.93 | +7% | Neutral | |
| $2.21 | $3.10 | $4.72 | -1% | Neutral | |
| $2.16 | $3.10 | $4.83 | -1% | Neutral | |
| $2.61 | $3.84 | $6.12 | +23% | Bullish | |
| $2.67 | $4.01 | $6.51 | +28% | Bullish | |
| $2.76 | $4.22 | $6.98 | +35% | Bullish | |
| $2.82 | $4.39 | $7.39 | +41% | Bullish | |
| $3.38 | $5.75 | $10.38 | +84% | Bullish | |
| $4.14 | $8.21 | $16.40 | +163% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.36 | $3.12 | $3.69 | +0.00% |
| June 2026 | $2.66 | $3.14 | $3.80 | +0.62% |
| July 2026 | $2.57 | $3.07 | $3.78 | -2.28% |
| August 2026 | $2.63 | $3.16 | $3.93 | +2.90% |
| September 2026 | $2.67 | $3.23 | $4.07 | +2.34% |
| October 2026 | $2.59 | $3.16 | $4.01 | -2.33% |
| November 2026 | $2.59 | $3.17 | $4.06 | +0.51% |
| December 2026 | $2.71 | $3.33 | $4.30 | +5.16% |
Click any year to see its month-by-month ACON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aclarion, Inc.'s 2026 outlook centres on $3.12, within a $2.36 to $4.30 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACON could reach as high as $4.94, with a base case around $3.60 and support toward $2.79 — roughly +15% from $3.12. A consolidation phase looks the most probable path here.
Expect ACON to range from $2.42 to $4.61 through 2028. The $3.22 average target implies a +3% move from current prices. That is -11% versus the projected 2027 average. Price action looks broadly range-bound.
The ACON price prediction for 2029 points to an average of $3.33 (low $2.43, high $4.93) — a potential gain of +7% on today's $3.12. A consolidation phase looks the most probable path here.
In 2030, ACON is projected to trade between $2.21 and $4.72, averaging $3.10 — a potential decline of -1% from today's $3.12. That is -7% versus the projected 2029 average. Price action looks broadly range-bound.
Aclarion, Inc.'s 2031 outlook centres on $3.10, within a $2.16 to $4.83 range. That is 0% versus the projected 2030 average. That marks a -1% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ACON could reach as high as $6.12, with a base case around $3.84 and support toward $2.61 — roughly +23% from $3.12. Momentum favours further upside here.
Expect ACON to range from $2.67 to $6.51 through 2033. The $4.01 average target implies a +28% move from current prices. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACON price prediction for 2034 points to an average of $4.22 (low $2.76, high $6.98) — a potential gain of +35% on today's $3.12. Momentum favours further upside here.
In 2035, ACON is projected to trade between $2.82 and $7.39, averaging $4.39 — a potential gain of +41% from today's $3.12. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Aclarion, Inc.'s 2040 outlook centres on $5.75, within a $3.38 to $10.38 range. That is up +31% on the projected 2035 average. That marks a +84% change versus current levels. Momentum favours further upside here.
By 2050, ACON could reach as high as $16.40, with a base case around $8.21 and support toward $4.14 — roughly +163% from $3.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACON today (≈ 320.512821 ACON) could be worth
$2,631.69
+$1,631.69 (+163%) by 2050 · US Dollar
Based on the average projected ACON price of $8.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACONwould be worth at today's price.
$1,000 invested in ACON on May 27, 2025 (≈ 145.348835 ACON) would be worth
$453.49
-$546.51 (-54.7%) today · 0.45× · US Dollar
Based on a ACON entry price of $6.88 vs. today's $3.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.19 | $978.06 | -2.2% |
| 1 month ago | $3.37 | $925.82 | -7.4% |
| 3 months ago | $2.68 | $1,164.18 | +16.4% |
| 6 months ago | $6.26 | $498.4 | -50.2% |
| 1 year ago | $6.88 | $453.49 | -54.7% |
| All time (4.1y) ago | $393,638.41 | $0.01 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACON forecast.
Our base-case forecast reaches $6.20 around 2050.
Implied market cap at $6.20: $15.27M
The multi-year forecast shows a nuanced path. For 2026 the min price is $2.36, the avg is $3.21, and the max is $4.46, with ROI 0 and sentiment NEUTRAL. In 2032 and beyond, the outlook becomes more bullish, with 2032 avg $3.97 (ROI 23.6) and 2033 avg $4.10 (ROI 27.9); 2034 avg $4.35 (ROI 35.7) and 2035 avg $4.53 (ROI 41.2).
By 2040 the avg price is projected at $5.93 with ROI 84.7, and by 2050 the avg reaches $8.47 with ROI 164. These forecasts imply a shift from neutral near-term momentum to stronger long-term upside, though these are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
2030 min $2.26, avg $3.18, max $4.84, roiPct -0.9, sentiment NEUTRAL.
The 2026 forecast is neutral with avg $3.21 and ROI 0. From 2032 onward, the outlook turns bullish with higher average prices and ROIs (e.g., 2032 ROI 23.6, 2033 ROI 27.9, 2040 ROI 84.7, 2050 ROI 164), but these are estimates and not guarantees.
Yes. The 2040 forecast lists a max of $10.71, which exceeds $10, indicating the upper bound of the projection in that year.
Current price is $3.21 and market cap is $7.9M.
The 30-day range is $2.58 to $3.99. Key support is $3.10 and resistance is $3.73.
Aclarion, Inc. Community Discussion
0Share your Aclarion, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.